Nature Medicine, Published online: 14 April 2026; doi:10.1038/s41591-026-04314-9
Two individuals with KCNT1-related epileptic encephalopathy were treated with a KCNT1-targeting antisense oligonucleotide, leading to significant reductions in seizure frequency and intensity, but also the development of hydrocephalus.
